Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago (safinamide) in Canada
Zambon, partner of Therapeutics biopharmaceutical company Newron, has entered into a partnership with Valeo Pharma, a specialty pharmaceutical company dedicated to registering and launching innovative prescription products in Canada.
The partnership grants Valeo exclusive rights to commercialise Zambon’s Parkinson’s disease product, Xadago (safinamide) in the Canadian market
This is a new treatment option for estimated 100,000 Canadians living with Parkinson's disease.
Xadago has been launched in Germany, Switzerland, Spain, Italy, Belgium, Denmark, Sweden, UK, Luxembourg, the Netherlands and Norway. It has recently been approved by the US Food and Drug Administration.
Under the terms of the agreement, Valeo Pharma will be responsible for all regulatory, sales and marketing, quality, and distribution activities in Canada.
“Xadago will be the first new oral treatment in almost 15 years to address this serious condition in Canada,” said Steve Saviuk, President of Valeo Pharma.
Roberto Tascione, CEO of Zambon said: “Entering Canada is an important step forward in the acceptance of safinamide for patients with PD already treated with L-dopa or other therapeutic combinations.”